Three cases of paralytic poliomyelitis associated with type 3 vaccine poliovirus strains in Bulgaria

Journal of Medical Virology

Volumn 81, Issue 9, 2009, Pages 1661-1667

  Korsun, Neli ^a   Kojouharova, Mira ^a   Vladimirova, Nadezhda ^a   Fiore, Lucia ^b   Litvinenko, Ivan ^c   Buttinelli, Gabriele ^b   Fiore, Stefano ^b   Voynova Georgieva, Violeta ^a   Mladenova, Zornitsa ^a   Georgieva, Daniela ^d  

^a NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES   (Bulgaria)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c University Pediatric Hospital   (Bulgaria)

^d RIOKOZ Bourgas ^*  (Bulgaria)

Author keywords

Acute flaccid paralysis; Oral poliovirus vaccine; Poliovirus

Indexed keywords

ANTIBIOTIC AGENT; ORAL POLIOMYELITIS VACCINE; VITAMIN K GROUP;

ARTICLE; BULGARIA; CASE REPORT; ENTEROCOLITIS; FLACCID PARALYSIS; HUMAN; INFANT; MALE; PNEUMONIA; POLIOMYELITIS; POLIOMYELITIS VIRUS; POLIOMYELITIS VIRUS 1; POLIOMYELITIS VIRUS 3; RADIODIAGNOSIS; VIRUS ISOLATION; VIRUS MENINGITIS; VIRUS STRAIN;

5' UNTRANSLATED REGIONS; ADULT; BULGARIA; CHILD; CHILD, PRESCHOOL; FECES; HUMANS; INFANT; INFANT, NEWBORN; MALE; POINT MUTATION; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINES; RECOMBINATION, GENETIC; SEQUENCE ANALYSIS, DNA;

POLIOVIRUS;

EID: 68949160957     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21545     Document Type: Article

References (31)

1. Buttinelli G, Donati V, Fiore S, Marturano J, Plebani A, Balestri P, Soresina AR, Vivarelli R, Delpeyroux F, Martin J, Fiore L. 2003. Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis. J Gen Virol 84:1215-1221. (Pubitemid 36592614)
2. Cann AJ, Stanway G, Hughes PJ, Minor PD, Evans DM, Schild GC, Almond JW. 1984. Reversion to neurovirulence of the liveattenuated Sabin type 3 oral poliovirus vaccine. Nucleic Acids Res 12:7787-7792.
3. Cherkasova EA, Korotkova EA, Yakovenko ML, Ivanova OE, Eremeeva TP, Chumakov KM, Agol VI. 2002. Long-term circulation of vaccine-derived poliovirus that causes paralytic disease. J Virol 76:6791-6799.
4. De Jesus N, Franco D, Paul A,Wimmer E, Cello J. 2005. Mutation of a single conserved nucleotide between the cloverleaf and internal ribosome entry site attenuates poliovirus neurovirulence. J Virol 79:14235-14243. (Pubitemid 41552721)
5. Evans DM, Dunn G, Minor PD, Schild GC, Cann AJ, Stanway G, Almond JW, Currey K, Maizel JV, Jr. 1985. Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature 314:548-550.
6. Friedrich F. 1996. Genomic modifications in Sabin vaccine strains isolated from vaccination-associated cases, healthy contacts and healthy vaccinees. Acta Virol 40:157-170. (Pubitemid 26285112)
7. FurioneM, Guillot S, Otelea D, Balanant J, CandreaA,Crainic R. 1993. Polioviruses with natural recombinant genomes isolated from vaccine-associated paralytic poliomyelitis. Virology 196:199-208. (Pubitemid 23247207)
8. Georgescu MM, Balanant J, Macadam A, Otelea D, Combiescu M, Combiescu AA, Crainic R, Delpeyroux F. 1997. Evolution of the sabin type 1 poliovirus in humans: Characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis. J Virol 71:7758-7768. (Pubitemid 27391722)
9. Gnanashanmugam D, Falkovitz-Halpern MS, Dodge A, FangM,Wong LJ, Esparza M, Hammon R, Rivas-Merelles EE, Santos JI, Maldonado Y. 2007. Shedding and reversion of oral polio vaccine type 3 in Mexican vaccinees: Comparison of mutant analysis by PCR and enzyme cleavage to a real-time PCR assay. J Clin Microbiol 45:2419-2425. (Pubitemid 47295468)
10. Gromeier M, Wimmer E. 1998. Mechanism of injury-provoked poliomyelitis. J Virol 72:5056-5060.
11. Gromeier M, Alexander L, Wimmer E. 1996. Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants. Proc Natl Acad Sci USA 93:2370-2375. (Pubitemid 26104357)
12. Guest S, Pilipenko E, Sharma K, Chumakov K, Roos RP. 2004. Molecular mechanisms of attenuation of the sabin strain of poliovirus type 3. J Virol 78:11097-11107. (Pubitemid 39299650)
13. Guillot S, Caro V, Cuervo N, Korotkova E, Combiescu M, Persu A, Aubert-Combiescu A, Delpeyroux F, Crainic R. 2000. Natural genetic exchanges between vaccine and wild poliovirus strains in humans. J Virol 74:8434-8443. (Pubitemid 30666694)
14. John TJ. 2004. A developing country perspective on vaccine-associated paralytic poliomyelitis. Bull World Health Organ 82:53-57. (Pubitemid 38220343)
15. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. 2005. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Ann Rev Microbiol 59:587-635.
16. Kilpatrick DR, Ching K, Iber J,Campagnoli R, Freeman CJ, Mishrik N, Liu HM, Pallansch MA, Kew OM. 2004. Multiplex PCR method for identifying recombinant vaccine-related polioviruses. J Clin Microbiol 42:4313-4315. (Pubitemid 39296164)
17. Kohler KA, Hlady WG, Banerjee K, Sutter RW. 2003. Outbreak of poliomyelitis due to type 3 poliovirus, northern India, 1999-2000: Injections a major contributing factor. Int J Epidemiol 32:272-277. (Pubitemid 36622274)
18. Kojouharova M, Zuber PL, Gyurova S, Fiore L, Buttinelli G, Kunchev A, Vladimirova N, Korsun N, Filipova R, Boneva R, Gavrilin E, Deshpande JM, Oblapenko G, Wassilak SG. 2003. Importation and circulation of poliovirus in Bulgaria in 2001. Bull World Health Organ 81:476-481. (Pubitemid 36909172)
19. Kuntchev A, Kojuharova M, Gjurova S, Korsum N, Fiore L. 2001. Imported wild poliovirus caused poliomyelitis-Bulgaria 2001. CDC-MMWR 50:1033-1035.
20. Martin J, Samoilovich E, Dunn G, Lackenby A, Feldman E, Heath A, Svirchevskaya E, Cooper G, Yermalovich M, Minor PD. 2002. Isolation of an intertypic poliovirus capsid recombinant from a child with vaccine-associated paralytic poliomyelitis. J Virol 76:10921-10928. (Pubitemid 35176209)
21. Martinez CV, Old MO, Kwock DK, Khan SS, Garcia JJ, Chan CS, Webster R, Falkovitz-HalpernMS,Maldonado YA. 2004. Shedding of sabin poliovirus type 3 containing the nucleotide 472 uracil-tocytosine point mutation after administration of oral poliovirus vaccine. J Infect Dis 190:409-416. (Pubitemid 38951984)
22. Parvaneh N, Shahmahmoudi S, Tabatabai H, Zahraei M, Mousavi T, Esteghamati AR, GooyaMM,Mamishi S,NateghR,KewOM. 2007. Vaccine-associated paralytic poliomyelitis in a patient with MHC class II deficiency. J Clin Virol 39:145-148.
23. Poliomyelitis. 1999.Norms and Standards in Epidemiology: Guidelines for epidemiological surveillance-Poliomyelitis. Epidemiol Bull 20:11-13.
24. Rahimi P, Tabatabaie H, Gouya MM, ZahraieM,MahmudiM, Ziaie A, Rad KS, Shahmahmudi Sh, Musavi T, Azad TM, Nategh R. 2007. Characterization of mutations in the VP (1) region of Sabin strain type 1 polioviruses isolated from vaccine-associated paralytic poliomyelitis cases in Iran. J Clin Virol 39:304-307. (Pubitemid 47079007)
25. Sabin AB. 1957. Present status of attenuated live virus poliomyelitis vaccine. Bull NY Acad Med 33:17-39.
26. Strebel PM, Sutter RW, Cochi SL, Biellik RJ, Brink EW, Kew OM, Pallansch MA, Orenstein WA, Hinman AR. 1992. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 14:568-579.
27. Strebel PM, Ion-Nedelcu N, Baughman AL, Sutter RW, Cochi SL. 1995. Intramuscular injections within 30 days of immunization with oral poliovirus vaccine: A risk factor for vaccine-associated paralytic poliomyelitis. N Engl J Med 332:500-506.
28. Svitkin YV, Cammack N, Minor PD, Almond JW. 1990. Translation deficiency of the Sabin type 3 poliovirus genome: Association with an attenuating mutation C472- -U. Virology 175:103-109. (Pubitemid 20093065)
29. WHO. 2003. Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries. Wkly Epidemiol Rec 78:241-250.
30. WHO. 2004. Polio laboratory manual. Geneva: World Health Organization. http://www.who.int/vaccines/en/poliolab/WHO-Polio- Manual-9.pdf.
31. WHO. 2006. Inactivated poliovirus vaccine following oral poliovirus vaccine cessation. Wkly Epidemiol Rec 81:137-144.